| General Information of Drug Metabolite (DM) (ID: DM000223) |
| DM Name |
Lapatinib ditosylate metabolite M1-glucuronide conjugate
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
UDP-glucuronyltransferase (UGT)
|
DMEN064
|
| Conjugation - Glucuronidation |
Lapatinib ditosylate
|
[1] , [2] , [1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Lapatinib ditosylate |
DR0917
|
Approved |
Breast cancer |
|
|
| References |
| 1 |
Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib Drug Metab Dispos. 2021 Mar;49(3):233-244. doi: 10.1124/dmd.120.000236.
|
| 2 |
Case Study 11: Considerations for Enzyme Mapping Experiments-Interaction Between the Aldehyde Oxidase Inhibitor Hydralazine and Glutathione. Methods Mol Biol. 2021;2342:809-823. doi: 10.1007/978-1-0716-1554-6_30.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
